Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcturus Therapeutics Holdings (ARCT) Return on Sales (2018 - 2025)

Arcturus Therapeutics Holdings' Return on Sales history spans 8 years, with the latest figure at 4.04% for Q4 2025.

  • For Q4 2025, Return on Sales fell 272.0% year-over-year to 4.04%; the TTM value through Dec 2025 reached 0.8%, down 27.0%, while the annual FY2025 figure was 0.8%, 27.0% down from the prior year.
  • Return on Sales reached 4.04% in Q4 2025 per ARCT's latest filing, down from 0.78% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.74% in Q4 2022 to a low of 27.11% in Q1 2021.
  • Average Return on Sales over 5 years is 5.41%, with a median of 0.79% recorded in 2025.
  • Peak YoY movement for Return on Sales: tumbled -2354bps in 2021, then soared 2605bps in 2022.
  • A 5-year view of Return on Sales shows it stood at 6.5% in 2021, then soared by 111bps to 0.74% in 2022, then tumbled by -151bps to 0.38% in 2023, then tumbled by -248bps to 1.32% in 2024, then plummeted by -207bps to 4.04% in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Return on Sales are 4.04% (Q4 2025), 0.78% (Q3 2025), and 0.32% (Q2 2025).